0 113

Cited 4 times in

The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C

Authors
 Zobair M. Younossi  ;  Maria Stepanova  ;  Linda Henry  ;  Kwang‐Hyub Han  ;  Sang Hoon Ahn  ;  Young‐Suk Lim  ;  Wan‐Long Chuang  ;  Jia‐Horng Kao  ;  Nguyen Kinh  ;  Ching Lung Lai  ;  Man‐Fung Yuen  ;  Henry Lik‐Yuen Chan  ;  Wei Lai 
Citation
 LIVER INTERNATIONAL, Vol.38(7) : 1179-1187, 2018 
Journal Title
 LIVER INTERNATIONAL 
ISSN
 1478-3223 
Issue Date
2018
Keywords
direct-acting antivirals ; mental health ; physical functioning ; sofosbuvir ; vitality
Abstract
BACKGROUND: Interferon (IFN)-based regimens cause significant impairment of health-related quality of life (HRQL). Hepatitis C virus (HCV) cure with IFN-free regimens improves HRQL. The effect of these regimens on HRQL in East Asian HCV patients is unclear due to lack of published evidence. AIM: To assess HRQL in East Asian HCV patients treated with an IFN-free regimen with sofosbuvir+ribavirin. METHODS: Patients completed Short Form-36 (SF-36) before, during and after treatment. RESULTS: 686 subjects were included (China: 56.7%; S. Korea: 18.8%; Taiwan: 12.7%; genotype 2: 40.8%; genotype 1: 29.6%; genotype 3: 18.4%; genotype 6: 11.2%; cirrhosis: 13.4%; treatment-naïve: 66.5%). Patients received either pegylated-IFN, sofosbuvir, and ribavirin (IFN+SOF+RBV) for 12 weeks (n = 155, genotypes 1 and 6) or SOF+RBV for 12-24 weeks (n = 531, all genotypes). The SVR-12 rates were 95.5% and 96.0%; respectively (P = .76). Baseline HRQL scores were similar between treatment groups (all P > .05). By the end of treatment, the IFN-treated group experienced significant declines in most HRQL scores (on average, by up to -13.3 points on a 0-100 scale from the baseline level, P < .02) while subjects on SOF/RBV had milder impairments (up to -5.4 points). Achieving SVR-12 was associated with HRQL improvement regardless of regimen (up to +2.9 points, P < .05). The use of IFN-free treatment was a consistent independent predictor of higher HRQL scores during treatment (β: +2.1 to +10.7 points, P < .02). CONCLUSIONS: East Asian HCV patients treated with an IFN-free regimen had better on-treatment HRQL scores. These data should inform policymakers about the comprehensive benefits of IFN-free regimens in East Asian patients with HCV.
Full Text
https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13650
DOI
10.1111/liv.13650
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/167607
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse